Investor information

Welcome to the Investor Relations section of the Verona Pharma website

This area is dedicated to keeping shareholders and potential investors up to date with our news, share price, and other relevant information.

We are committed to delivering our strategy and creating both near-and long-term value to our shareholders.

Current share price

132.50p

-1.50 (-1.12%)

LON: VRP
London Stock Exchange

Latest press releases

19 April 2017

Verona Pharma Announces Launch of Global Offering and Application to List on the NASDAQ Global Market
19 April 2017, London - Verona Pharma p…
Read press release

18 April 2017

Verona Pharma Receives Authorization from the U.S. FDA to Proceed with Clinical Investigation of RPL554 with the Acceptance of Investigational New Drug Application
18 April 2017, London – Verona Pharma plc (AIM: VRP) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, announced today that the U.S. Food and Drug Administration has authorized the initiation of a pharmacokinetic (“PK”) clinical trial in the U.S. for the Company’s product candidate, RPL554, with the acceptance of an Investigational New Drug appli…
Read press release

Downloads

Annual report 2016

Our latest annual report for the year ended 31 December 2016 is available in our downloads section

Shareholder information

Capital structure

The Company's issued share capital consists of 51,361,064 ordinary shares with a nominal value of 5p each ("Ordinary Shares"), each share having equal voting rights. The Company does not hold any Ordinary shares in treasury and therefore the number of Ordinary Shares with voting rights is 51,361,064.

In accordance with AIM Rule 26, in so far as the Company is aware, the percentage of the Company's issued share capital that is not in public hands is 41.1%. The percentage of the Company's issued share capital held by the Directors and management is 0.6%.

A number of European and US healtchare specialist investment firms have invested in the Company. At 13 February 2017, the Company has been notified, in accordance with sections 198 to 208 of the Companies Act 1985, of the interests in excess of 3% of the Company’s issued share capital set out in the table.

Shareholder No. of shares % of Issued Share Capital
Novo 6,464,065 12.6
Vivo Capital 6,309,847 12.3
OrbiMed 4,669,847 9.1
New Enterprise Associates 4,424,065 8.6
Abingworth 3,510,553 6.8
Aviva 3,285,974 6.4
Rothschild 2,212,033 4.3
Tekla 2,212,033 4.3
Wales Life Sciences Investment Fund 2,110,000 4.1
Fidelity 1,805,944 3.5

Corporate governance

Corporate social responsibility

The Board of Directors of Verona Pharma recognises the importance of sound corporate governance and strives, where practicable for a company of its size and nature, to comply with the standards of good practice prescribed by the UK Corporate Governance Code (2012) in its four specified areas:

  • Board leadership and effectiveness
  • Directors' remuneration
  • Accountibility with respect to financial practices
  • Relations with shareholders

For a copy of the UK Corporate Governance Code (2012), visit the UK Financial Reporting Council (FRC) website at www.frc.org.uk

The Board of Directors has established an Audit Committee, a Remuneration Committee and a Nominations and Corporate Governance Committee, with formally delegated duties and responsibilities.

 


Share dealing code

The Company has adopted a share dealing code in order to ensure compliance with the EU Market Abuse Regulation and Rule 21 of the AIM Rules.

Download the Verona Pharma Share dealing code

Anti-corruption & bribery policy

The Company has adopted an anti-corruption and bribery policy in order to ensure compliance with the UK Bribery Act (2010). The Board has appointed a "compliance officer" to oversee compliance with the policy.

Download the Verona Pharma Anti-corruption & bribery policy

AIM Rules compliance policy

The Company has adopted an AIM Rules compliance policy in order to ensure compliance with Rule 31 of the AIM Rules.

Download the Verona Pharma AIM Rules compliance policy


Audit Committee

Mr Vikas Sinha
Dr David Ebsworth
Dr Andrew Sinclair

Download Audit Committee terms of reference

Remuneration Committee

Dr Ken Cunningham
Dr David Ebsworth
Mr Rishi Gupta

Download Remuneration Committee terms of reference

Nominations Committee

Dr David Ebsworth
Dr Mahendra Shah
Dr Anders Ullman

Download Nominations Committee terms of reference

Financial calendar

Annual General meeting

12 April 2017, 12:00pm – 6th Floor, 60 Gracechurch Street, London EC3V 0HR

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us